Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 4/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28905052 | 0.97 | MGLL (0.39) | ALDH1A1GAAMAPTTHRBMGLL | |
| SCHEMBL11701401 | 0.95 | TSHR (0.39) | ALDH1A1GAAMAPTTHRBTSHR | |
| SCHEMBL6893925 | 0.87 | PER2 (0.37) | ALDH1A1GAATSHRPER2KDM4E | |
| SCHEMBL10973875 | 0.82 | PRKAB2 (0.38) | GAAPER2PTGS2SMN1; SMN2PRMT5 | |
| SCHEMBL1446475 | 0.81 | PRMT5 (0.36) | ALDH1A1GAAPER2SMN1; SMN2PRMT5 | |
| SCHEMBL31309 | 0.81 | ALDH1A1 (0.43) | ALDH1A1GAAMAPTTHRBMGLL | |
| SCHEMBL3568870 | 0.80 | SMN1; SMN2 (0.47) | ALDH1A1GAAPER2SMN1; SMN2PRMT5 | |
| SCHEMBL16908831 | 0.80 | POLB (0.38) | GAAPER2KDM4ESMN1; SMN2PRMT5 | |
| SCHEMBL1446480 | 0.80 | PRKAB2 (0.39) | ALDH1A1GAATSHRPER2KDM4E | |
| SCHEMBL15885015 | 0.80 | PRKAB2 (0.39) | GAAPER2PTGS2SMN1; SMN2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5635103-A | Bleaching compositions and additives comprising bleach activators having alpha-modified lactam leaving-groups | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-03 | — | — | US | claimed |
| EP-1773823-B1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-08-21 | — | — | EP | disclosed |
| CN-101006084-B | 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS | 2010-09-08 | — | — | CN | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| CN-101006084-A | 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-07-25 | — | — | CN | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| EP-1773823-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006021654-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-03-02 | — | — | WO | disclosed |
| US-5635103-A | Bleaching compositions and additives comprising bleach activators having alpha-modified lactam leaving-groups | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | ALDH1A1 503/4885GAA 3459/4885MAPT 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.